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A B S T R A C T
A673T mutation in the amyloid precursor protein (APP) is a rare variant associated with a reduced risk of late-onset Alzheimer‘s disease (AD) and age-related
cognitive decline. The A673T mutation decreases beta-amyloid (Aβ) production and aggregation in neuronal cultures in vitro. Here we have identified a Finnish non-
diseased male individual carrying a heterozygous A673T mutation, obtained a skin biopsy sample from him, and generated an iPSC line using commercially available
integration-free Sendai virus-based kit. The established iPSC line retained the mutation, expressed pluripotency markers, had a normal karyotype, and differentiated
into all three germ layers in vitro.
Resource Table:
Unique stem cell line ide-
ntifier
UEFi003-A
Alternative name(s) of st-
em cell line
MADGIC 12B
Institution A.I.Virtanen Institute for Molecular Sciences
University of Eastern Finland
Contact information of di-
stributor
Šárka Lehtonen, sarka.lehtonen@uef.fi; sarka.leh-
tonen@helsinki.fi
Type of cell line iPSC
Origin Human
Additional origin info Age: 58
Sex: male
Ethnicity if known: Finnish
Cell Source Skin fibroblasts
Clonality Clonal
Method of reprogramming Sendai virus delivery of OCT-3/4, KLF-4, SOX-2 and c-
MYC genes
Genetic Modification Yes
Type of Modification Hereditary
Associated disease Protective against Alzheimer‘s disease
Gene/locus APP (MIM # 104760) located on the chromosome
21q21.3 genotype Chr21: 25,897,620 G > A substitu-
tion (rs63750847)
Method of modification NO modification
Name of transgene or re-
sistance




Date archived/stock date N/A
Cell line repository/bank Registered in hPSCreg.eu
Ethical approval Northern Savo Hospital district (license no. 123/2016)
1. Resource utility
Aβ aggregates in the brain are the main hallmark of AD pathology.
The A673T mutation in APP reduces the production of Aβ peptides. The
generated line could be used to study the effects of a decreased Aβ
production on neuronal cell function alone and in co-cultures with glial
cells.
2. Resource details
APP is an evolutionarily well-conserved type I transmembrane
glycoprotein. Its cleavage can produce several different products, in-
cluding β-amyloid (Aβ), the accumulation of which has long been
considered as the major driving force in AD pathogenesis. The A673T
mutation in APP strongly decreases APP cleavage by beta-secretase 1,
thus reducing the generation of Aβ peptides and soluble APP-β (Jonsson
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et al., 2012; Maloney et al., 2014). It is also increasingly recognized that
APP plays an important role in normal physiological processes
(Brothers et al., 2018). APP is upregulated early in the development,
and its cleavage products can regulate neurogenesis, neuronal migra-
tion, synapse formation and activity (Nicolas and Hassan, 2014). Aβ is
also known to have antimicrobial activity (Brothers et al., 2018). We
have previously reported the generation of an iPSC line from a 65-year
old male expressing a rare Chr21: 25,897,620 G > A variant
(rs63750847) in the APP gene (Lehtonen et al., 2018). Here we have
recruited another 58-year-old healthy (without neurological condi-
tions) Finnish male individual carrying the same mutation and gener-
ated a new iPSC line (Table 1).
Fibroblasts were reprogrammed using CytoTune™-iPS 2.0 Sendai
Reprogramming Kit. The colonies were manually picked and expanded
clonally in feeder-free conditions on Matrigel coating. Here, we present
the detailed characterization for clone MADGIC 12B. As expected,
MADGIC 12B cells were positive for pluripotency markers OCT-4,
NANOG, TRA-1-81 (podocalyxin), and SSEA4 as demonstrated by im-
munocytochemical staining (Fig. 1B). The cells also strongly upregu-
lated NANOG, SOX2, and LIN28 and downregulated Sendai virus (SeV)
gene expression compared to the parental fibroblasts shown by quan-
titative real-time PCR (Fig. 1C). Chromosomal analysis showed a
normal karyotype (Fig. 1E). STR analysis confirmed the identical ge-
netic background of the donor fibroblasts and the iPSC clone (data
available from the authors). PCR amplification of APP locus followed by
Sanger sequencing confirmed the presence of a heterozygous Chr21:
25,897,620 G > A mutation (Fig. 1F). In addition, MADGIC 12B line
formed embryoid bodies (EBs) when plated in the ultra-low adherent
plate. Immunocytochemical analysis of the EBs was performed after
28 days of culture. It showed a spontaneous differentiation into cell
types representative of the three embryonic germ layers, including
smooth muscle antibody (SMA)-positive cells (mesoderm), alpha-feto-
protein (AFP)-positive cells (endoderm) and beta-III-tubulin (B-III-
TUB)-positive cells (ectoderm) (Fig. 1G). A PCR-based mycoplasma
detection test was negative (Fig. 1D).
3. Materials and methods
3.1. Generation of induced pluripotent stem cells
Punch skin biopsy was collected from a healthy male individual
recruited by Kuopio University Hospital, Finland, after obtaining in-
formed consent. Skin fibroblasts were expanded as described previously
(Lehtonen et al., 2018) and transduced using CytoTune™-iPS 2.0 Sendai
Reprogramming Kit (Thermo Fisher Scientific) according to the man-
ufacturer’s instructions in fibroblast culture medium containing Iscove's
DMEM with 20% fetal bovine serum, 1% penicillin–streptomycin and
1% non-essential amino acids (all from Thermo Fisher Scientific). At
day 6 post-transduction, fibroblast culture medium was replaced with
Essential 6 Medium (E6, Thermo Fisher Scientific) supplemented with
100 ng/ml basic fibroblast growth factor (bFGF; Peprotech). At three
weeks post-transduction, individual reprogrammed iPSC colonies were
selected based on morphology and re-plated onto Matrigel (growth
factor reduced; Corning; 1:200)-coated 24-well plates. Four iPSC clones
were further expanded and grown routinely in feeder-free conditions in
Essential 8 Medium (Thermo Fisher Scientific) on Matrigel-coated
(1:200) 3.5 cm dishes at 37 °C 5% CO2. The cells were passaged with
0.5 mM EDTA every 4–5 days.
3.2. Genetic analysis
To confirm identical genetic background of the derived clone and
parental fibroblasts, thirteen microsatellite loci (D8S1179, D21S11,
D16S538, D2S1338, D18S51, VWA_CHR12, FGA_CHR4, D10S1248,
D12S391, D4S385a/b, SE33, CSF1PO and HPTRB; Table 2) were ana-
lyzed by conventional PCR using MyTaq DNA polymerase (Bioline).
Genomic DNA was isolated from the cells using the NucleoSpin Tissue
Mini DNA extraction kit (Macherey-Nagel). PCR products were resolved
by running electrophoresis for 1.5 h on a 3% agarose gel in TBE buffer.
The presence of the A673T mutation was confirmed by PCR and Sanger
sequencing performed at the Institute for Molecular Medicine Finland
(FIMM), University of Helsinki (primers listed in Table 2, Rev-primer
used for sequencing).
3.3. Embryoid body formation
To prove our new iPSC line's ability to differentiate to all three germ
layers spontaneously, we performed an embryoid body (EB) formation
assay. IPSCs colonies were detached by using ReLeSR passaging reagent
(StemCell Technologies) and cultured in suspension for two weeks in
ultra-low adherent 6-well plates (Corning) containing DMEM medium
supplemented with 20% Serum replacement and 1% Penicillin-
Streptomycin (Thermo Fisher Scientific). Afterwards, EBs were re-
plated onto Matrigel-coated 24-well plates and left to differentiate for
two more weeks. The scale bar for EBs in suspension is 200 µm.
3.4. Quantitative RT-PCR and immunocytochemistry
RNA was extracted using the RNeasy Mini kit (Qiagen), and quan-
titative RT-PCR was done using commercially available Taqman probes
(Table 2) according to the manufacturer’s instructions. For im-
munocytochemistry, plated iPSCs and EBs were fixed in 4% for-
maldehyde for 20 min at room temperature and stained with the pri-
mary antibodies (Table 2) diluted in 5% normal goat serum in PBS with
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Visual record of the line: normal Fig. 1 panel A
Phenotype Immunocytochemistry Positive staining of pluripotency markers: Oct4, Nanog, TRA-1-81,
SSEA4
Fig. 1 panel B
RT-qPCR Expression of Lin28, Nanog, Sox2 Fig. 1 panel C
Genotype Karyotype (G-banding) and resolution 46 XY
Resolution of 400 band level
Fig. 1 panel E
Identity STR analysis 13 sites tested, all matched with parental fibroblasts cell line available with author
Mutation analysis Sequencing Heterozygous
p.A673T in APP
Fig. 1 panel F
Microbiology and virology Mycoplasma Mycoplasma testing by PCR. Negative. Fig. 1 panel D
Differentiation potential Embryoid body formation Positive staining for smooth muscle actin (SMA), beta-III-tubulin
(BIIITub) and α-feto protein (AFP)
Fig. 1 panel G
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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Fig. 1.
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the exception of Nanog antibody, which was diluted in 0.1% bovine
serum albumin in PBS, at 4 °C overnight. For the staining of nuclear
markers, cells were permeabilized with 0.2% Triton X-100. The fol-
lowing day, the secondary antibodies (1:300 dilution, Table 2) were
added for 1 h at room temperature. Images were taken using a Zeiss
AXIO microscope. Scale bars are 100 µm for iPSCs and 50 µm for plated
EBs.
3.5. Karyotype analysis
Karyotyping was performed using Giemsa (G-banding) staining as
described (Lehtonen et al., 2018). Twenty metaphases were analyzed.
The analyses were performed at the Yhtyneet Medix laboratoriot,
Table 2
Reagents details.
Antibodies used for immunocytochemistry

















R&D Systems; cat. AF1997;
RRID:AB_355097
EMD Millipore; cat. MAB4381;
RRID:AB_177638
































Molecular Probes; cat. A11001;
RRID:AB_2534069
Molecular Probes; cat. A11004;
RRID:AB_2534072
Molecular Probes; cat. A11057;
RRID:AB_142581
Primers







Antibodies used for immunocytochemistry
























































Thermo Fisher Scientific; cat. Hs02387400_g1
Thermo Fisher Scientific; cat. Hs00702808_s1
Thermo Fisher Scientific; cat. Hs01053049_s1
Housekeeping
Genes (qPCR)
ACTB Thermo Fisher Scientific; cat. 4326315E
Sendai virus SeV Thermo Fisher Scientific; cat.
Mr04269880_mr




The absence of mycoplasma contamination was confirmed by PCR
reaction targeting mycoplasma-specific 16S ribosomal RNA (primer
sequence listed in Table 2) followed by gel electrophoresis.
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